Oxaliplatin is a platinum-based chemotherapy drug characterized by the development of a painful peripheral neuropathy which is reproduced in rodent animal models with features observed in humans. Our focus was to explore the alterations of intracellular second messengers at supraspinal level in oxaliplatin-induced mechanical hyperalgesia. In our experiments, chronic administration of oxaliplatin to rats induced mechanical hyperalgesia which lasted for many days. When the hyperalgesic rats were submitted to paw pressure test in the presence of selective PKC inhibitor Calphostin C supraspinally administered, hyperalgesic effect could be reversed showing that PKC activity in supraspinal brain regions is needed. Concurrently, oxaliplatin chronic treatment induced a specific upregulation of c isoforms of PKC and increased phosphorylation of c/e PKC isoforms within thalamus and PAG. Phosphorylation was reversed when PKC activity was inhibited by Calphostin C. Distinct PKC-activated MAPK pathways, including p38MAPK, ERK1/2 and JNK, were investigated in chronic oxaliplatin rat. A dramatic phosphorylation increase, Calphostin C sensitive, could be observed in thalamus and PAG for p38MAPK. These data show that, in oxaliplatin-induced neuropathy, enhanced mechanical nociception is strictly correlated with increased phosphorylation of specific intracellular mediators in PAG and thalamus brain regions pointing to a role of these supraspinal centers in oxaliplatin-induced neuropathic pain mechanism. Ó
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Introduction
Oxaliplatin[(trans-l)1,2-diaminocyclohexaneoxalatoplatinum(II)] is a platinum-based chemotherapy drug whose cytotoxicity is thought to result from inhibition of DNA synthesis. The use of the antineoplastic drug oxaliplatin for the treatment of a variety of cancers is significantly limited by the development of a painful peripheral neuropathy characterized by both an acute sensitivity to cold and lack of sensation in the hands and feet and a chronic foot/leg, hand/arm numbness [3] . It has previously been reported that oxaliplatin produces a peripheral neuropathy in rats in several well-characterized animal models with features observed in humans [5] . Thus, oxaliplatin induces acute mechanical hyperalgesia after intravenous single dose administration [11] ; repeated intravenous oxaliplatin enhances mechanical hyperalgesia and allodynia, heat allodynia and cold allodynia in rodents [2] indicating sensitization in the peripheral and central nociceptive system. Although the mechanism lying beneath the acute neuronal excitability and pain induced by oxaliplatin is still to be determined, it has been ascribed, at least in part, to a specific interaction of oxaliplatin with specific isoforms of the voltage-gated sodium channels, located in the cellular membrane, increasing the excitability of sensory neurons, an effect that has been suggested to play a role in pain syndrome experienced by oncologic patients [9, 10] . Although investigations of the mechanism of neuropathic pain induced by platinum-based chemotherapy drug have been a major focus of interest for the last years, neuropathic pain is a major chronic condition that presently remains difficult to treat for solid tumor chemotherapy. In the present study we tested whether alterations of intracellular second messengers at supraspinal level are revealed in oxaliplatin-induced mechanical hyperalgesia.
Materials and methods

Animals
Male Sprague-Dawley rats weighing between 200 and 300 g (Harlan Inc., Varese, Italy) were used. During the experiment, the animals were fed with commercial cubes and drinkable water ad libitum and maintained in an air-conditioned housing room (23 ± 1°C) with a 12-h light-dark cycle. All animal procedures were performed according to the European Economic Community 
